In vitro profiling of the potent and selective PI3K inhibitor AEZS-126

被引：0

作者：

Seipelt, Irene ^{[1
]}

Gerlach, Matthias ^{[1
]}

Blumenstein, Lars ^{[1
]}

Mueller, Gilbert ^{[1
]}

Teifel, Michael ^{[1
]}

Polymeropoulos, Emmanuel ^{[1
]}

Guenther, Eckhard ^{[1
]}

机构：

[1] Aeterna Zentaris GmbH, Frankfurt, Germany

来源：

CANCER RESEARCH | 2009年 / 69卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[1] AEZS-126, a new orally bioavailable PI3K inhibitor in preclinical development
Seipelt, Irene
Baasner, Silke
Gerlach, Matthias
Teifel, Michael
Fensterle, Joachim
Blumenstein, Lars
Mueller, Gilbert
Guenther, Eckhart
CANCER RESEARCH, 2009, 69
[2] Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ
Allen, Rodger A.
Brookings, Daniel C.
Powell, Mark J.
Delgado, Jean
Shuttleworth, Lindsay K.
Merriman, Mark
Fahy, Ian J.
Tewari, Roohi
Silva, John P.
Healy, Louise J.
Davies, Gareth C. G.
Twomey, Breda
Cutler, Rona M.
Kotian, Apoorva
Crosby, Andrea
McCluskey, Gillian
Watt, Gillian F.
Payne, Andrew
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2017, 361 (03): : 429 - 440
[3] Dual PI3K/ERK inhibitor AEZS-136, a potent antitumor compound under preclinical development
Gerlach, Matthias
Seipelt, Irene
Blumenstein, Lars
Jung, Kai
Schuster, Tilmann
Mueller, Gilbert
Guenther, Eckhard
Engel, Juergen
Teifel, Michael
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
[4] Discovery of a novel and potent mutant-selective inhibitor of PI3Kα
Gao, Mingming
Qi, Chao
Li, Zhentian
Fan, Qipeng
Wang, Liyang
Zhou, Fei
You, Lin
Zheng, Hewen
Li, Yu
Wu, Liangxing
Yao, Wenqing
Liu, Phillip C.
CANCER RESEARCH, 2024, 84 (06)
[5] Optimization and in vivo evaluation of pyrazolopyridines as a potent and selective PI3Kδ inhibitor
Hamajima, Toshihiro
Takahashi, Fumie
Kato, Koji
Sugano, Yukihito
Yamaki, Susumu
Moritomo, Ayako
Kubo, Satoshi
Nakamura, Koji
Yamagami, Kaoru
Hamakawa, Nozomu
Yokoo, Koji
Fukahori, Hidehiko
BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (14) : 3917 - 3924
[6] In vitro characterization of AMG 511, a potent and selective class I PI3K inhibitor for the treatment of cancer
Caenepeel, Sean
Zhang, Nancy
Wang, Ling
Norman, Mark H.
Burgess, Terri
Radinsky, Robert
Kendall, Rick
Freeman, Daniel
Hughes, Paul E.
CANCER RESEARCH, 2012, 72
[7] AEZS-129, an orally active PI3K inhibitor in preclinical development
Seipelt, I.
Guenther, E.
Baasner, S.
Blumenstein, L.
Mueller, G.
Fensterle, J.
Engel, J.
Teifel, M.
Gerlach, M.
EJC SUPPLEMENTS, 2010, 8 (07): : 38 - 38
[8] Discovery of Potent and Selective PI3Kγ Inhibitors
Drew, Samuel L.
Thomas-Tran, Rhiannon
Beatty, Joel W.
Fournier, Jeremy
Lawson, Kenneth, V
Miles, Dillon H.
Mata, Guillaume
Sharif, Ehesan U.
Yan, Xuelei
Mailyan, Artur K.
Ginn, Elaine
Chen, Jie
Wong, Kent
Soni, Divyank
Dhanota, Puja
Chen, Pei-Yu
Shaqfeh, Stefan G.
Meleza, Cesar
Pham, Amber T.
Chen, Ada
Zhao, Xiaoning
Banuelos, Jesus
Jin, Lixia
Schindler, Ulrike
Walters, Matthew J.
Young, Stephen W.
Walker, Nigel P.
Leleti, Manmohan Reddy
Powers, Jay P.
Jeffrey, Jenna L.
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (19) : 11235 - 11257
[9] Targeting aberrant PI3K pathway signaling with XL147, a potent, selective and orally bioavailable PI3K inhibitor
Shapiro, Geoffrey I.
Edelman, Gerald
Calvo, Emiliano
Aggarwal, Sanjay K.
Laird, A. Douglas
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3594S - 3594S
[10] ANTITUMOR ACTIVITY OF PI3K ANTAGONIST AEZS126*IN MODELS OF TRIPLE NEGATIVE BREAST CANCER
Engel, J. B.
Schmidt, H.
Haeussler, S.
Diessner, J.
Hahne, J.
Meyer, S.
Wischhusen, J.
Dietl, J.
Hoenig, A.
ANTICANCER RESEARCH, 2011, 31 (05) : 1967 - 1968

← 1 2 3 4 5 →